| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.037 | 0.6 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |